This work was funded through a contract with AccessCare North Carolina.
Dr. Farley has been a consultant to Novartis and Daiichi-Sankyo. Dr. Sikich has received research funding in the past three years from or participates in clinical trials sponsored by Bristol-Myers Squibb, Curemark, Merck, Forest, Otsuka Research Institute, SynapDx, and Seaside Pharmaceuticals, and she has received software for a computer intervention in schizophrenia from Posit Science. The other authors report no competing interests.